Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) – Pipeline Review, H2 2017’, provides in depth analysis on Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Musculoskeletal Disorders, Cardiovascular, Metabolic Disorders, Ophthalmology, Dermatology, Oncology, Respiratory, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Immunology and Infectious Disease under development targeting Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

The report reviews Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics and enlists all their major and minor projects

The report assesses Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Amgen Inc

Amorepacific Corp

AnaBios Corp

BCN Peptides SA

Daewoong Pharmaceutical Co Ltd

DoNatur GmbH

Flex Pharma Inc

Grunenthal GmbH

Kyowa Hakko Kirin Co Ltd

Medifron DBT Co Ltd

Neurim Pharmaceuticals Ltd

Pila Pharma AB

Sylentis SAU

Toray Industries Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Overview

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Companies Involved in Therapeutics Development

Amgen Inc

Amorepacific Corp

AnaBios Corp

BCN Peptides SA

Daewoong Pharmaceutical Co Ltd

DoNatur GmbH

Flex Pharma Inc

Grunenthal GmbH

Kyowa Hakko Kirin Co Ltd

Medifron DBT Co Ltd

Neurim Pharmaceuticals Ltd

Pila Pharma AB

Sylentis SAU

Toray Industries Inc

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Drug Profiles

AMG-986 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1119 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

capsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

capsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMX-020 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DD-04107 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-05195 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-787 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-788 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-797 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FLX-798 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

K-685 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MCS-18 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-16523 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDR-652 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit TRPV1 for Inflammatory Pain and Cancer Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-6860 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NeuP-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAC-14028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Target TRPV1 for Pain and Itch - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

piromelatine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

QX-314 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

resiniferatoxin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Overactive Bladder - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate TRPV1 Channel for Pain and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPA1 and TRPV1 for Central Nervous System - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPA1 and TRPV1 for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Block TRPV1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SYL-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XEND-0501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zucapsaicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Dormant Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Discontinued Products

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Product Development Milestones

Featured News & Press Releases

Aug 01, 2017: Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US

Jul 25, 2017: FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS

Jul 20, 2017: Centrexion Therapeutics to Present Phase 2b Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma at the American Podiatric Medical Association 2017 Annual Scientific Meeting

Jun 29, 2017: Sorrento Therapeutics Announced FDA Authorization of IND to Commence Clinical Trial of RTX in Intractable Cancer Pain

Jun 13, 2017: Centrexion Therapeutics Announces New 6-Month Data Demonstrating Significant and Durable Pain Relief with CNTX-4975 for Treatment of Moderate to Severe Knee Osteoarthritis Pain

Jun 07, 2017: Centrexion Therapeutics Announces Oral Presentation of Six Month Efficacy Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at the Annual European Congress of Rheumatology

Jun 02, 2017: Flex Pharmas Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium

May 30, 2017: Sylentis initiates a Phase III study for the treatment of dry eye syndrome

May 25, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Knee Osteoarthritis at European Federation of National Associations of Orthopaedics and Traumatologys 2017 Annual Congress

May 10, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 for the Treatment of Chronic Pain Associated with Morton’s Neuroma and Knee Osteoarthritis at American Pain Society 2017 Annual Scientific Meeting

May 09, 2017: PharmaMar: Sylentis Announces New Preclinical and Clinical Data for its SYL1001 Molecule During ARVO 2017

Apr 26, 2017: FDA Clears Flex Pharmas FLX-787 to Commence US Phase 2 Trial in ALS Under IND

Apr 19, 2017: Flex Pharma Presents Human Efficacy Data on FLX-787 at the American Academy of Neurology Annual Meeting

Apr 05, 2017: Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development

Mar 23, 2017: Centrexion Therapeutics to Present Data on CNTX-4975 from the Treatment of Knee Osteoarthritis Pain at IX SIMPAR-ISURA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by Amgen Inc, H2 2017

Pipeline by Amorepacific Corp, H2 2017

Pipeline by AnaBios Corp, H2 2017

Pipeline by BCN Peptides SA, H2 2017

Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Pipeline by DoNatur GmbH, H2 2017

Pipeline by Flex Pharma Inc, H2 2017

Pipeline by Grunenthal GmbH, H2 2017

Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017

Pipeline by Medifron DBT Co Ltd, H2 2017

Pipeline by Neurim Pharmaceuticals Ltd, H2 2017

Pipeline by Pila Pharma AB, H2 2017

Pipeline by Sylentis SAU, H2 2017

Pipeline by Toray Industries Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Dormant Products, H2 2017 (Contd..3), H2 2017

Dormant Products, H2 2017 (Contd..4), H2 2017

Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports